#### 1 Title:

3

10

11

12

13

14

15

16

19

20 21

22

23

24 25

26

27 28

### Vaccination mitigates climate-driven disruptions to malaria control 2

- 4 **Authors**
- Benjamin L. Rice<sup>1</sup>\*, Estelle Raobson<sup>2,3</sup>, Sylviane Miharisoa<sup>4</sup>, Mahery Rebaliha<sup>5,6</sup>, Joseph Lewinski<sup>6</sup>, 5
- 6 Hanitriniaina Raharinirina<sup>2</sup>, Bryan Greenhouse<sup>7</sup>, Christopher D. Golden<sup>5,8</sup>, Gabriel A. Vecchi<sup>9,10</sup>, Amy
- Wesolowski<sup>11</sup>, Bryan Grenfell<sup>1,12</sup>, C. Jessica E. Metcalf<sup>1,12</sup> 7 8

#### 9 Affiliations

- 1. Department of Ecology and Evolutionary Biology, Princeton University; Princeton, NJ, USA.
- 2. Mention Zoologie et Biodiversité Animale, University of Antananarivo; Antananarivo, Madagascar.
- 3. Association Vahatra; Antananarivo, Madagascar.
- 4. Institut Pasteur de Madagascar; Antananarivo, Madagascar.
- 5. Madagascar Health and Environmental Research (MAHERY); Maroantsetra, Madagascar.
- 6. Multisectoral Malaria Project, Catholic Relief Services; Baltimore, MD, USA.
- 17 7. EPPIcenter Program, Division of HIV, Infectious Diseases, and Global Medicine, Department of 18 Medicine, University of California San Francisco; San Francisco, CA, USA.
  - 8. Department of Nutrition, Harvard TH Chan School of Public Health; Boston, MA, USA.
    - 9. Department of Geosciences, Princeton University; NJ, USA.
    - 10. High Meadows Environmental Institute, Princeton University; NJ, USA.
      - 11. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; Baltimore, MD, USA.
      - 12. Princeton School of Public and International Affairs, Princeton University; Princeton, NJ, USA.

\*Corresponding author. Email: b.rice@princeton.edu

### Abstract 29

- Increasingly extreme weather events in high malaria burden areas threaten progress to disease 30
- 31 control targets. Yet, data on the impact of these events on control programs remain rare. Using
- unique data from Madagascar, we estimate high rates of infection in the wake of two major 32
- tropical cyclones. Evidence that infection rebounds rapidly during gaps in interventions indicates 33
- 34 maintaining continuity of coverage is crucial to limiting burden. Relative to other interventions,
- 35 recently available malaria vaccines have a longer duration of protection, with the potential to
- address interruptions in prevention deployment. Evaluating this use case, we quantify the 36
- 37 reduction in symptomatic infections expected for a range of vaccination scenarios. We find long-
- lasting interventions such as vaccination are a key mitigation measure against climatic 38
- disruptions to disease control. 39
- 40
- 41
- 42
- 43
- 44
- 45

## 46 Main Text

- 47 Malaria remains a major global health challenge (1, 2). Much work has investigated how the
- 48 coincident challenge of climate change threatens progress to malaria control (1). Rising
- 49 temperatures modify mosquito vector dynamics (3-5), altering infection risk (6, 7), but these
- 50 impacts are often focused in low burden areas at the altitudinal and latitudinal margins of malaria
- 51 transmission (8-10). By contrast, extreme weather events, with some types likely to increase in
- 52 frequency or severity due to climate change (11-14), disrupt public health efforts (15-19),
- 53 including in areas where the burden of malaria is concentrated. Data on the impact of climate-
- related disasters on malaria infection remain rare (18, 20, 21), despite high rates of exposure to
- such events in malaria endemic settings and the clear importance of disruptions amidst the
- 56 changing landscape of malaria control activities.
- 57 In response to stalled progress in malaria control in high burden countries and the development
- of new treatment and prevention tools (1), the World Health Organization (WHO) and national
- 59 malaria control programs are preparing the large-scale deployment of new interventions. These
- 60 include scaling the mass distribution of antimalarial chemoprophylaxis and treatment (e.g.,
- 61 seasonal or perennial malaria chemoprophylaxis, SMC, PMC), and vaccination (see **Table S1**).
- 62 Continuity is important to all of these interventions, as their effectiveness erodes over time, thus
- 63 requiring regular re-administration. Extreme weather events threaten that continuity by delaying
- 64 or degrading public health activities (18). Understanding the barrier this poses to achieving
- 65 malaria control targets requires detailed data on infection risk during periods of likely disruption.
- 66 However, limitations in surveillance systems make such data rare.
- 67 Tropical cyclones are an example of extreme weather events repeatedly shown to disrupt health
- 68 systems for weeks to months following the event (21-26). Madagascar, our focus here, is subject
- 69 to regular tropical cyclones (Figure 1), resulting in widespread destruction, population
- displacement, and damage to healthcare-related infrastructure (**Data S1**). We leverage a unique
- 71 dataset comprising repeated measures of malaria infection status surrounding cyclone events (n =
- 72 20,718 observations) to develop a platform to explore the spectrum of recommended
- 73 interventions and their robustness under climate change.
- 74

## 75 **Results**

## 76 1. High rates of exposure to cyclones and malaria infection

- 77 *1.1 Cyclone frequency and disruptive effect in Madagascar*
- 78 Cyclone frequency and severity has increased in the southern Indian Ocean (27, 28) with storms
- 79 in Madagascar causing repeated humanitarian emergencies in recent years. Cyclones Batsirai and
- Freddy destroyed over 300 health facilities (29–32) and resulted in an estimated 112,115 and
- 81 290,000 people in need of immediate humanitarian assistance in 2022 and 2023, respectively
- 82 (33) (Figure 1D). Excess rainfall for Cyclone Batsirai was made more likely by increased

- 83 greenhouse gas and changes in aerosol emission per climate attribution studies (34). Our study
- site, Mananjary district, is located on the east coast of Madagascar, a moderate to high malaria
- 85 transmission area.
- 86
- 87
- 88 Figure 1: The scale of cyclone-malaria interactions globally and in Madagascar



90

- 91 Figure 1A: Blue lines show cyclone tracks from IBTrACS for all storms since 1980 (35, 36). Malaria incidence
- 92 estimates are from the Malaria Atlas Project (*37*). Inset: Intensity for the 1705 recorded storms impacting currently
- 93 malaria endemic countries since 1980 (defined as storm center approaching within 60 nautical miles of landfall). For
- boxplots, the midline shows the median number of storms in the period 1980-2023, lower and upper hinges
- correspond to the 25th and 75th percentiles and whiskers extend 1.5 times the interquartile range. Points show the
- number of storms for a given year, jittered for visibility. Categories follow the Saffir-Simpson wind scale for the
- 97 maximum wind speed observed within 60 nautical miles of landfall: Tropical Depression (TD), Tropical Storm (TS),
- 98 Hurricane Category 1-5 equivalent (H1-H5), or no wind speed data available (ND).
- 99





Guinea (PNG).



110 111 112 113

**Figure 1C**: Tropical cyclone tracks in Africa colored by year of the storm. Inset: Tropical storm activity is highest in southeast Africa with over 47.9% of impacts in Africa overall contributed by Madagascar and Mozambique.



Figure 1D: Tropical cyclone activity for Madagascar since 1980 with the study district, Mananjary, outlined. Tracks show the estimated path of the storm center, with those passing within 60 nautical miles (111.1 km) of the Mananjary district shown in blue (others in gray). Two examples of recent cyclones impacting the Mananjary district, Cyclone Batsirai and Cyclone Freddy, are highlighted with estimated wind speed (data from IBTrACS) and estimates of the number of individuals requiring humanitarian assistance (data from EM-DAT).

#### 121 1.2 Characterizing malaria infection rates

- We characterize rates of malaria infection from a longitudinal cohort study of a random sample 122
- 123 of 500 households (2954 individuals, all ages) from 10 localities (Figure 2A). Repeated
- sampling of malaria infection status by rapid diagnostic test (RDT) was performed for the period 124
- July 2021-April 2023 (mean number of samples per enrolled individual = 7.7, median = 9) 125
- (Figure S1). The interval between samples was short (mean = 57.4 days, median = 52 days) 126
- 127 relative to the duration of an untreated P. falciparum infection (approx. 180 days (41, 42)),
- indicating a low probability of natural infection clearance prior to the next sample. All 128
- individuals positive for malaria were treated to clear infections, allowing estimates of rates of 129
- infection and re-infection (see methods). During the course of the study, the area was impacted 130
- by Cyclone Batsirai (February 5, 2022) and Cyclone Freddy (February 21, 2023), providing 131
- estimates of malaria infection rates in the period before and for the 2 months after each event. 132
- 133
- 134



135

136

137 Figure 2A: Sampling locations for cohort study sites (MNJ.01-MNJ.10, ordered from north to south). Location of 138 the Mananjary urban area, the capital of the Mananjary district, shown with a square. District boundary shown in 139 white, elevation data from the Copernicus Global Digital Elevation Model (43).

21.8°5

47°F 48°F 49°E 50°E

140

48.4°E

48.6°E



141

Figure 2B: Raw malaria infection observations by rapid diagnostic test (RDT) by individual for the 10 follow-up
sampling time points (T01-T10) for the 10 sample localities in Mananjary District, Madagascar (MNJ.01-MNJ.10).
For visualization, each row is an individual (individuals with >50% of attendance at sampling time points shown)
with a random subsample of 100 individuals shown for each locality (full data in supplement). Inset: An overview of
sampling methods. RDT positive individuals are treated to clear infections and estimate time to re-infection. Some
infections are uncounted due a false negative RDT result (shown as circles with black outline and red fill).







## 152 *1.3 Malaria infection results: Force of infection and exposure following cyclones*

- 153 We derive estimates of the force of infection (FOI) by age and season from ten follow-up
- sampling time points (see methods) (Figure 2B). FOI peaked for school-aged children (Figure
- 155 S2), consistent with the higher frequency of infection commonly observed in this group (e.g.,
- 156 (44)). Transmission fluctuated seasonally, with the percentage of school-aged children expected
- to be infected within a month ranging, by site, from 0.8-9.1% in October to 4.9-44.3% in May
- 158 (Figure 2C). At the higher FOI sites (e.g., MNJ.01, MNJ.08, MNJ.09, MNJ.10), we estimate
- 159 13.5-35.6% of younger children and 20.0-49.1% of school aged children were exposed to
- 160 malaria infection in the 2 months following Cyclones Batsirai and Freddy (**Figure 2D**).
- 161 Equipped with these empirically derived estimates of the scale of the rate of infection, we can
- evaluate the potential impacts of disruptions to malaria control programs during cyclone season.
- 163

151





168 169

164

## 170 2. Malaria incidence is sensitive to brief disruptions in control

- 171 2.1 Supplemental malaria interventions in the context of disruption
- 172 Current operational plans for high malaria burden countries, including Madagascar (45),
- 173 recommend implementing or expanding interventions using anti-malaria drugs to reduce burden

in targeted populations, as a supplement to existing base activities (i.e., bednet distribution).

- 175 Approaches use the regular administration of either a standard first-line antimalarial with a short
- half-life (protective against reinfection for 13-15 days (46)) to clear existing infections (mass
- drug administration, MDA, or mass testing and treatment, MTaT) or a longer lasting antimalarial
- 178 (protective for 21-42 days (47, 48)) to also prevent new infections (seasonal or perennial malaria
- 179 chemoprophylaxis, SMC, PMC, or intermittent preventive treatment of malaria in pregnancy,
- 180 IPTp) (see **Table S1**).

## 181 *2.2 Consequences of temporal gaps in coverage*

182 We explore the deployment of each of these supplemental interventions across the observed

range of FOIs, introducing delays to follow-up administration rounds at different points along a

184 seasonal cycle (see methods). Following the cessation of drug administration, protection decays

185 at a rate determined by the drug half-life, and infections accumulate at a rate determined by the

- 186 FOI for that locality, age group, and seasonal period (**Figure 3A**). Historical cyclone data for
- 187 Madagascar indicates the time interval with the highest risk for storm impact occurs between
- January-April, contributing 81.8% of recorded tropical cyclones (Figure 3B). For a disruption
   that results in prophylactic protection ceasing on March 1st, we estimate 5.3-11.9% of younger
- children and 8.0-17.6% of school aged children are infected by day 20 in high FOI sites. This
- indicates that the temporary gaps in prophylaxis administration likely in the aftermath of extreme
- 192 weather events are a major challenge for control programs aiming to minimize burden (e.g.,
- 193 maintain infection below a 1% or 10% threshold) among vulnerable children.

## 194 2.3 Incidence results are robust to variation in the force of infection

Our initial estimates of FOI indicate that prevalence rebounds rapidly when drug-based treatment 195 and prevention coverage ceases (e.g., reaching 10% for school-aged children within 8-92 days by 196 197 site). Future changes to malaria transmission dynamics or uncertainty in initial estimation of FOI 198 may result in variation in the rate of rebound. For example, undercounting infected hosts due to imperfect RDT sensitivity will result in an underestimation of FOI (Figure S3). To account for 199 this, we evaluate a range of FOI scenarios (Figure 3C). Increasing FOI results in prevalence 200 reaching the threshold prevalence level sooner (e.g., for school aged children, reaching 10% 201 prevalence 3-31 days sooner for a 50% increase in FOI), demonstrating that rapid rebounds in 202 203 prevalence are robust to RDT sensitivity or other sources of underestimation. Alternatively, FOI 204 could be decreased by reductions in the intensity of transmission achieved by intervention rounds 205 prior to the disruption event. However, even in optimistic scenarios where earlier rounds of drug 206 administration substantially reduce transmission rates, prevalence rebounds are only slightly 207 delayed at high FOI sites (e.g., by 8-9 days for a 50% decrease in FOI for sites MNJ.01 and 208 MNJ.10). These data suggest chemoprevention-based intervention regimes with currently 209 available drugs are of limited efficacy in maintaining a low prevalence of infection in the face of 210 climate-driven disruptions for the FOI ranges likely in moderate to high transmission settings.

### 212 Figure 3: Modeled increase in malaria infection due to interrupted drug administration



Time
Figure 3A: Schematic for estimating the risk of malaria infection over time as a function of the force of infection (FOI) and the rate of decay of prophylactic protection. For example, an interruption to the re-administration of a short and long half-life chemoprevention drug is caused by a tropical cyclone (image source: NASA, Cyclone Batsirai, February 2, 2022).

218



219

**Figure 3B**: Left: Calendar date of recorded tropical storms impacting Madagascar since 1980. Right: The

cumulative probability of infection (i.e., the proportion of the susceptible population expected to be infected) for a
 31-day interval beginning on that day, shown for school aged children (13 years of age). Differences among sites are
 shown as rings.



Force of infection (FOI) scenario (% change relative to observed FOI) Figure 3C: Time until infection reaches a target prevalence versus the force of infection (FOI). A threshold of 10% prevalence is chosen as an example, corresponding to the WHO-defined upper limit for a low malaria burden setting. Baseline observed FOIs for March for the ten sampling localities in Mananjary district (shown with vertical dotted line) are increased or decreased by 0-99% for each site for four exemplar age groups. For reference, the dotted horizontal line shows 90 days (approx. 3 months), with the area under the horizontal line (outlined in red) corresponding to scenarios where the FOI is such that an interruption in access to chemoprevention of that duration results in infection exceeding the target threshold.

232

## 233 *3. Vaccination under climate-driven disruption to control*

## 234 3.1 Modeling vaccination

An exciting shift for malaria control is the recent availability of anti-malarial vaccines. Uniquely, 235 vaccines have a substantially longer duration of protection (i.e., > 10 months (49, 50)) than 236 currently used chemoprophylaxis drugs and the time interval relevant for seasonal, climate-237 238 driven disruptions such as tropical cyclones (i.e., 3-4 months). Additionally, vaccines using new 239 technology such as mRNA may improve upon the efficacy against clinical disease observed so 240 far for the recently authorized RTS,S (50-56%) (49) and R21 (68-75%) (50) vaccines. To evaluate the potential of vaccines to reduce malaria burden under climate disruptions, we 241 242 quantify the reduction in burden under a range of scenarios of vaccine coverage, efficacy, and symptomatic rates of infection (see methods) (Figure 4A). Symptomatic rates are obtained from 243 our cohort study where we find 37.0-53.2% of infections among children are associated with 244 observable symptoms (Figure S4), in line with previous estimates of asymptomatic infection 245 rates in moderate to high transmission settings (without vaccination) (51). 246

### Figure 4: Symptomatic malaria infection probabilities during disruption under a model of vaccination



### 249

250 Figure 4A: Probability tree of the outcomes of malaria infection under vaccination. Parameters on branches specify 251 the probability of either path at branching points. In the simplest analysis, the probability of symptomatic malaria 252 infection for an age group over a time period t is determined by the probability of infection,  $p(I) = 1 - e^{-\lambda t}$  where  $\lambda$  is 253 the force of infection, the vaccination coverage, v, the probability of symptoms given infection, s, and any protective 254 effect of vaccination, E. Vaccines may have efficacy against infection,  $E_i$ , or against symptoms,  $E_s$ . Note that when 255  $E_i$  is small, as is thought to be the case for currently available vaccines, the probability of infection is similar for 256 vaccinated, V, and unvaccinated, V', individuals. When  $E_s$  is large, vaccinated individuals are unlikely to have 257 symptoms upon infection.



### 258 259

Figure 4B: The percent reduction in the number of expected symptomatic infections across a range of vaccine efficacies. Without vaccination, the baseline probability of a symptomatic infection is  $s \cdot p(I)$ . Assuming  $E_i = 0$ , the percent reduction in symptomatic infections due to vaccination can be expressed as  $(s \cdot p(I) - (S_v + S_v)) / (s \cdot p(I))$ which simplifies to  $v \cdot E_s$ . Estimates for the efficacy of the two currently available anti-malaria vaccines, RTS,S (49) and R21 (50), are shown for example. The shaded quadrant shows the scenarios with sufficient efficacy and coverage to observe a 50% reduction in symptomatic infections.



Figure 4C: For the targeted subpopulation (i.e., children), the number of symptomatic malaria infections averted by vaccination with efficacy against symptoms  $E_S$ . Rows show results for four levels of infection rates, expressed as the cumulative proportion of the population expected to be infected over the time interval considered. Columns show results for three values for the probability with which infections become symptomatic.

## 273 *3.2 Vaccination has the potential to reduce malaria burden following extreme weather events*

274 When 70% of the targeted population has completed the full course for a vaccine with efficacy 68-75% (that reported for the R21 vaccine in phase 3 trials (50)) prior to the disruptive event, a 275 276 47.6-52.5% reduction in the expected proportion of symptomatic infections is expected (Figure **4B**). This level of vaccine coverage is plausible given the coverage (approx. 70%) reported for 277 routine childhood immunization in the country (52, 53). Existing estimates of vaccine efficacy 278 279 are obtained on high background rates of access to and use of bednets and other vector control 280 interventions (54). Estimates of bednet usage in Madagascar are 70-80% on the east coast of Madagascar (55) and at our study sites we estimate usage was 72.6-82.6% before and 69.4-281 282 76.4% after the two cyclone events (Figure S5). The number of cases averted is dependent on 283 the infection rate and the symptomatic rate. Using the observed parameter values for the highest force of infection site (MNJ.10) and 50-70% coverage with the R21 vaccine as an example, we 284 estimate, per 1000 children, a decrease from 135.1-193.5 symptomatic infections in the 2 months 285 following a February cyclone to 64.1-101.4 symptomatic infections under vaccination (with 286 287 45.9-101.6 cases averted, respectively) (Figure 4C).

288

266

272

#### 290 3.3 Vaccination results are robust to modest efficacy and coverage

Vaccine completeness or timeliness may be imperfect for a fraction of the population, for 291 292 example due to the timing of a child's birth relative to planned vaccination dates or missed vaccination rounds. Additionally, efficacy may wane in subsequent years (50). To account for 293

this variation in the degree of protection we explore a range of proportions of partially protected 294 295 individuals (Figure S6). We also explore a range of symptomatic infection probabilities,

296 including scenarios where symptomatic infection becomes more probable as infection derived

- immunity declines under lower incidence (Figure S7). We find vaccination can lead to a 297
- substantial reduction (i.e., approx. 50%) in the frequency of symptomatic malaria infection 298
- during disaster aftermath, results that are robust to even moderate vaccine efficacy and 299 reasonable vaccination coverage (Figure 4B-C). 300
- 301

### Discussion 302

#### 303 1. Temporal gap-filling as a potential use case for malaria vaccination

304 Leveraging a unique dataset from Madagascar, we demonstrate that discontinuities in protection 305 against malaria are a critical threat to efforts to reduce burden. Extreme weather events are a challenge to maintaining continuity. Climate change amplifies the risk of some extreme weather 306 events (56), including tropical cyclones (11), with potentially devastating consequences relevant 307 for health (18). The role of the disruptions likely to result from climate-driven disasters, and the 308 best options for response, have been neglected in the study of climate change and malaria. 309 Vaccination, recently available for malaria, has the unique feature of a protective effect sufficient 310 in duration to persist through disruptive events, such as cyclones and their aftermath. To date,

311

- 312 assessments of the cost-effectiveness of vaccination, and priority areas for vaccine deployment, do not account for the additional benefit of long lasting protection, even when moderate, against 313
- disease in times of disruption. Our findings suggest a new use case for vaccines, the deployment 314
- of vaccination in areas vulnerable to climate-driven or other disruption. 315
- 2. Limitations: Diagnostic uncertainty from reliance on RDTs and moderate vaccine efficacy 316

317 Ideally, estimates of infection rate would be determined with highly sensitive diagnostics (e.g.,

PCR) (51, 57). Here, as in many settings with limited access to advanced health infrastructure, 318

- diagnostic options were constrained to field-deployable, rapid diagnostics (e.g., RDTs). We 319
- developed a set of sensitivity analyses to allow inference under the expected diagnostic 320
- 321 uncertainty, with general applicability to other settings reliant on RDTs for surveillance. While
- 322 RDTs are likely to miss low parasitemia infections (58), the extent to which these contribute to
- 323 clinical burden, the target for vaccination, is unclear (41, 59). Additionally, as described above,
- 324 undercounting these infections minimally alters the magnitude of timing of infection rebound
- 325 relevant for disaster response.

326 As malaria control programs prepare to scale up interventions to meet ambitious targets in 327 coming years, investment across multiple control options must be evaluated (60). Benefits from 328 covering any temporal gaps in drug administration present an important case for considering vaccination, even given current shortcomings. Limited vaccine efficacy and questions as to cost-329 330 effectiveness across varied settings (61-63), alongside their minimal transmission blocking activity, and restricted age range for which data are available (e.g., children < 4 years) mean that 331 vaccines are unlikely to be deployed alone. Efforts that combine prevention approaches with 332 different kinetics, even though they may appear redundant during periods without disturbance, 333 are likely needed to mitigate the impact of extreme weather events. Such approaches could 334 335 include reinforcement of vector control interventions such as bednets during periods of population displacement (64–66), strengthening health facilities to minimize damage (67, 68), 336 and creative drug distribution approaches for prophylaxis that avoid dependence on storm-337 338 vulnerable infrastructure (for example, for intermittent preventive treatment during pregnancy,

339 IPTp).

## 340 *3. The need for more research on attribution and disaggregating mechanisms of risk*

341 A limitation of our study is reliance on estimates of aggregate risk of infection following a 342 climate event. A challenging but important task for future investigations will be to separate the 343 proportion of risk attributable to background and seasonal trends from the direct and indirect impacts of an extreme weather event. We hypothesize tropical cyclones alter the risk of infection 344 through multiple mechanisms such as flooding, population displacement, and destruction of 345 housing and clinics (18, 21, 69), that interact to modify mosquito vector abundance, host 346 347 exposure to infection, and access to and use of prevention and treatment. We find the overall magnitude of infection to be high, which will dictate the burden experienced during disaster 348 349 aftermath and the likely response to control measure scenarios. Obtaining further resolution, however, is limited by difficulty in deriving expectations for a non-cyclone impacted year for the 350 351 study area. This is due to the scarcity of long-term data with direct estimates of malaria infection rates and the high frequency of cyclones. Both cyclone seasons of the present study (2022 and 352 2023) featured major storms and, at the national scale, Madagascar has experienced 48 cyclones 353 with intensity at or greater than a category 1 hurricane in the 44 years since 1980. Additionally, 354 storms will interact with multi-year changes in underlying drivers of malaria risk, such as 355 356 periodic mass bednet campaigns, and any residual damage to infrastructure from previous years' storms. Despite these complexities around identifying a storm's possible impact on transmission 357 potential, critically, any decline in the continuity of access to healthcare and the deployment of 358 359 control measures will increase population exposure to transmission. As a result, data on total risk 360 of infection following a climate event, even when the fraction attributable to the event is low or uncertain, will be valuable for planning and should be a priority for future surveillance efforts. 361

## 362 *4. Implications for disease control in an era of increasingly extreme weather*

The overwhelming majority of global malaria cases and deaths come from a subset of African countries (e.g., 20 African countries contribute 86% of global cases) (1). The context of stalled

365	progress in control efforts in these high burden settings, the broad effects of climate change, new
366	recommendations for expanded chemoprevention, and the advent of vaccination create a new
367	environment for malaria control. Health system and infrastructural disruptions in these high
368	burden areas could be a major consequence of climate change for malaria. Continuity in public
369	health efforts will be decisive for global efforts to reduce the burden of this pathogen. Severe
370	tropical cyclones, a source of likely disturbance, have marked seasonality, making the timing of
371	their impact predictable and enabling anticipatory interventions such as vaccination. Other forms
372	of disturbance (e.g. civil conflict $(70, 71)$ ) may be less predictable in their timing, but could
372	benefit from similar analyses. In addition to malaria, other infectious diseases subject to control
373	regimes reliant on the regular distribution of drugs or vaccination may be vulnerable to climate-
275	driven disruption (23, 72). This warrants increased attention on the interaction between climate
375	and the continuity of public health access. Our date suggest in the melaric and transcel evaluates
570	and the continuity of public health access. Our data suggest, in the mataria and tropical cyclones
3//	case, vaccination – less sensitive to short term disruption – will be a key mitigation measure.
378	
379	
380	
381	
382	
383	
384	
385	
200	
288	
389	
390	
391	
392	
393	
394	
395	
396	
397	
398	
399	
400	
401	
402	
403	
404 405	
405	
406	

# 407 Acknowledgements

- 408 We thank the CRS Multisectoral Malaria Project staff for support and the CRS Madagascar office and
- 409 Mananjary malaria project staff for assistance with data collection: Dr. Virginie Andreas Nambinina
- 410 Ralisoa, Dr. Elanirina Andrianoelivololona, Elodie Mialinjaka Rabarijaona, Tahiniony Tonie Ludjette
- 411 Rakotozafy, Johnson Rakotohasimbola, Juloce Lidovique Razafindrakoto, Hermann Raelison Paratoaly,
- 412 Aymardine Flashe Kantomananjara, Simon Razafindrasoja, Arisoa Beatrice Marie Sandrine Niry, and
- 413 James Hazen. We thank the High Meadows Environmental Institute (HMEI) at Princeton University for
- 414 support.
- 415 Funding:
- 416 CRS SCP4 Multisectoral Malaria Project (BLR, SM, MR)
- 417 The Falcon Award for Disease Elimination The Climate Edit by the Global Institute for Disease
- 418 Elimination (GLIDE) (BLR, MR)
- 419 The Ren Che Foundation and the AWS Impact Computing Project at the Harvard Data Science Initiative
- 420 (HDSI) (CDG)
- 421 The High Meadows Environmental Institute (HMEI) at Princeton University (BLR, GAV, CJEM)

### 422 Author contributions:

- 423 Conceptualization: BLR, MR, JL, BG, CDG, AW, BG, CJEM
- 424 Methodology: BLR, BG, AW, BG, CJEM
- 425 Investigation: BLR, ER, SM, MR, HR
- 426 Visualization: BLR, BG, CJEM
- 427 Funding acquisition: BLR, MR, JL, CDG
- 428 Project administration: BLR, MR, JL
- 429 Writing original draft: BLR, BG, CJEM
- 430 Writing review & editing: BLR, ER, JL, GAV, AW, BG, CDG, CJEM
- 431 Competing interests:
- 432 Authors declare that they have no competing interests.
- 433 Data and materials availability:
- All data are available in the main text or the supplementary materials. Code and date files are available at
- 435 a github repository: <u>https://github.com/bennyrice/mananjary\_cyclone\_code</u>
- 436
- 437
- 438
- 439
- 440
- 441
- \_
- 442
- 443
- 444

# 445 **Supplementary Materials**

446

# 447 Materials and Methods

## 448 1. Study area: Mananjary district, southeastern Madagascar

Located in southeastern Madagascar, the Mananjary district (region Vatovavy) is a coastal district with
 perennial malaria transmission. The district extends approximately 60 km to the north and south of the

district capital, the city of Mananjary (-21.22 S, 48.35 E) where the only hospitals in the district are
located. As of 2018, 90.1% of the population of the district lives in rural *kaomina* ("communes") (Institut

- 452 located. As of 2018, 90.1% of the population of the d453 National de la Statistique Madagascar).
  - 454 From Malaria Indicator Surveys, malaria prevalence among children 5 years or younger in the east coast
  - of Madagascar averaged 9-18% from 2011 to 2021 (55, 73–75), placing the district in the WHO defined
  - 456 moderate transmission stratum. In terms of seasonality, higher prevalence was estimated for December to
- 457 May from re-analyses of health facility data (76, 77), with a peak around April (78). Few recent
- 458 epidemiological studies with active sampling are available from the region, but prevalence among
- households (all ages) varied from 3-46% by locality in 2017 from cross-sectional prevalence surveys (44, 79).

## 461 **2. Extreme weather event data**

462 Historical data on the occurrence of extreme weather events was sourced from the National Oceanic and

- 463 Atmospheric Administration (NOAA) International Best Track Archive for Climate Stewardship
- 464 (IBTrACS) data (accessed 21 February 2024) and EM-DAT from the Centre for Research on the
- 465 Epidemiology of Disasters (CRED) (accessed 21 February 2024). See Data S1 for the full list of weather
   466 events.
- 467 Search criteria were all storms where the eye passed within a 60 nautical mile (approx. 111 km) buffer of
  468 Madagascar's coastline. This buffer was chosen because extreme rainfall and winds may extend across
  469 the diameter of a storm. Tropical cyclones are defined as systems with maximum sustained wind speeds >
- 470 119 km/h, equivalent to a Category 1 Hurricane per the Saffir-Simpson scale used in the Atlantic basin.

## 471 **3. Longitudinal sampling**

- 472 *3.1 Prospective cohort study*
- 473 A stratified random sample of 500 households evenly distributed among 10 rural sampling clusters
- 474 (communities or *tanana*) were recruited and enrolled during a baseline sample in July-October 2021.
- 475 Informed consent or assent was obtained for study participants prior to enrollment. Enrolled households
- 476 were followed longitudinally for 10 follow-up sampling time points. Clusters were rural (defined as more
- than 5km from the Mananjary district capital) and approximately 10 km apart on average.
- 478 Study procedures received approval from the Institutional Review Board (IRB) of the Harvard T.H. Chan
- 479 School of Public Health (IRB#21-0111), Comité d'Ethique de la Recherche Biomédicale (CERBM) at
- 480 Ministère de la Santé Publique de Madagascar (N°019/MSANP/SG/AMM/CERBM 2021), the Mananjary
- 481 district health office, local government authorities, and community leaders.

482 Figure S1 shows the proportion of the cohort negative, positive, and unsampled by rapid diagnostic test

(RDT) per time point. The participation rate, calculated as the percentage of enrolled individuals

screened, ranged from 62.5-91.0% per time point. We consider individuals with visible bands for lactate

- 485 dehydrogenase (LDH) or histidine rich protein 2 (HRP2) antigens as positive. The RDTs used were the
- AccessBio CareStart<sup>™</sup> Pf/Pan RDT or Abbott Diagnostics Bioline<sup>™</sup> Malaria Ag Pf/Pan RDT per
   manufacturer's protocol.

## 488 *3.2 Screening for malaria and symptoms*

All individuals in enrolled households were screened for malaria at approximately 2-month intervals (mean interval between samples = 57.4 days, median = 52 days, n = 20,718 total observations). On site diagnosis by RDT was performed at the time of screening and a blood sample was collected on a dried blood spot (DBS) for later molecular confirmation. Individuals, or a surrogate for younger children, also completed a questionnaire on bednet usage and symptoms adapted from refs. (80, 81). Sensitivity

analyses were performed to account for RDT sensitivity and specificity (**Figure S3**).

Individuals positive for malaria by RDT were offered treatment by an onsite physician with artemisininbased combination therapy (ACT) using the standard first line treatment for Madagascar (artesunate
amodiaquine, AS+AQ). To observe treatment adherence, at minimum the first dose of the three-day
course of treatment was observed directly by the research team. Symptomatic individuals or individuals

498 requesting a consultation were offered a consultation with an onsite physician.

500 *3.3. Accounting for RDT sensitivity and specificity* 

501 Due to imperfect sensitivity and specificity for RDTs, false positive and false negative RDT results may

502 bias inference of infection rates. From a previous study, an estimated 97% of infections in the east coast

503 region of Madagascar are by *Plasmodium falciparum* and 88% of RDT positive infections were

504 confirmed by molecular follow-up (82). In studies of diagnostic performance, RDT sensitivity and

specificity was estimated to be approximately 80-90% (83, 84).

- 506 We use a binomial sampling approach to explore the effect of diagnostic error. We simulate 'false
- 507 negatives' by drawing from a binomial distribution with probability 1 sensitivity such that a fraction of 508 RDT negatives become positive. Likewise, we simulate 'false positives' by drawing from a binomial
- RDT negatives become positive. Likewise, we simulate 'false positives' by drawing from a binomial
   distribution with probability equal to the *specificity* such that a fraction of RDT positives become
- 505 Instruction with probability equal to the *specificity* such that a fraction of KD1 positives become 510 negative. **Figure S3** shows simulations over a range of sensitivity and specificity values, where we repeat
- 511 the force of infection estimation methods (described in the following section) for 500 replicates. These
- 512 results illustrate minimal bias across plausible ranges of sensitivity and specificity. When the proportion
- 513 of positive tests is small, accounting for possible false negatives results in an increase in the expected
- 514 proportion infected. For sites with a high proportion of positive tests (i.e., approximately 50%), false
- 515 negatives and false positives are similarly likely such that the expected proportion infected is minimally
- 516 changed.

## 517 4. Estimating the force of infection

518 The interval before infection probability reaches a given threshold will hinge on target prevalence and the

519 rate at which individuals become reinfected. To evaluate this, we define  $\lambda$  as the force of infection, or rate

520 at which susceptible individuals become infected. The catalytic model (85) then defines the probability of

521 evading infection up until time *t* as:

$$S(t) = exp(-\lambda t)$$

523 and the probability of having been infected by time *t* (or cumulative density function of infection) is

524 
$$F(t) = l - exp(-\lambda t)$$

525 For malaria, infected individuals are susceptible to reinfection. The rate at which this occurs within the

526 time interval of interest will be negligible when the force of infection is low and/or the time interval

527 considered is short, estimated to be the case here (e.g., within 1-2 months). We consequently proceed with 528 the estimates based on F(t).

Because no evidence of resistance to ACT antimalarials has been reported to date from Madagascar, we
assume the clearance rate of asexual and sexual stages of the parasite to be high. Given our direct
observation of the early doses of anti-malarial treatment for infected individuals, we assume adherence to
the treatment course is high and successful clearance of parasite infections following treatment. Thus for

individuals positive at  $t_i$  and  $t_{i+1}$  we assume that a new infection has occurred over the time interval.

534 The force of infection may vary according to time-invariant covariates such as geographic site, and

535 individual age (which can be considered approximately time-invariant at least over the time-scales

536 considered). We can fit these quantities using a generalized linear model fitted with a binomial likelihood

using a complementary log-log link, such that if  $\pi_i$  is the probability of being infected over interval *i*, the

538 link function is provided by  $\eta_i = log (-log (1 - \pi_i))$ . The cumulative density function can then be

539 expressed as:  $F(\eta_i) = l - exp(-exp(\eta_i))$  from which it can be deduced that the link function must

- 540 take the form  $\eta_i = \beta X_i + \log(t)$  where  $\beta$  is a vector of coefficients, and  $X_i$  is the corresponding design
- 541 matrix of covariates for interval *i*. Introducing this back into the cumulative density function yields

542 
$$F(t) = 1 - exp\left(-exp\left(\beta X_i + log(t)\right)\right) = 1 - exp\left(-(\beta X_i)\right)$$

543 indicating that the force of infection is defined by:  $(\beta X_i)$ , as desired (86).

To additionally capture seasonal fluctuations in the force of infection (by their nature time-varying), we can introduce covariates reflecting the number of days each individual at each measurement was exposed to different seasons of transmission (e.g., days in each month); and we can additionally introduce smooth terms to capture non-linear patterns. The extended force of infection is then provided by:

- 548  $\left(\alpha_{site,i} + s(age_i) + \gamma_1 M_{1,i} + \gamma_2 M_{2,i} + \gamma_3 M_{3,i} + \cdots\right)$
- 549 Where the parameter  $\alpha$  takes a different value for each of the ten study sites;  $s(age_i)$  indicates a

smoothed pattern across age,  $M_{j,i}$  reflects the number of days an individual *i* was exposed to the  $j^{th}$ 

month of the year, with  $\gamma_i$  the corresponding parameter converting this into effects on the force of

552 infection. Finally, we also include a random effect for household, as there was evidence of consistent

553 effects across households. The final expression for the force of infection is thus:

554 
$$(\alpha_{site,i} + s(age_i) + \gamma_1 M_{1,i} + \gamma_2 M_{2,i} + \gamma_3 M_{3,i} + \dots + H_i)$$

555 Where  $H_i$  corresponds to the random effect mapping the household of individual *i*.

### 556 5. Exploring the consequences of disruptions during intervention rollout

To explore the deployment of new mass chemoprevention and chemotherapy interventions, we simulatethe early phases of these interventions, when the program is building towards, but has not yet, interrupted

transmission. As a result, ongoing transmission results in the reaccumulation of infections, at a rate

560 determined by the force of infection, following each intervention round until transmission is interrupted

- 561 (i.e., force of infection approaches 0). We first investigate the return time, which we define as the
- 562 maximum time interval between intervention rounds for a given force of infection where malaria
- prevalence is maintained below a chosen target level in the targeted population (see supplementary
- methods for full details).

565 The required program return time  $\Delta_c$  necessary to maintain prevalence below a chosen threshold z is 566 defined by:

567 
$$\Delta_c = \frac{-\log (I)}{\lambda}$$

568 The estimated force of infection captures the rate at which individuals become infected, and interventions 569 occur at intervals of  $\Delta$  days, and clear  $p_t$  percent of infections. Conservatively, we assume clearance for

-z)

570 treated individuals to be 100% such that treatment successfully reduces infectiousness and treated

571 individuals do not participate in transmission. This is supported by the lack of evidence of resistance to

572 ACTs in Madagascar to date and evidence ACTs clear gametocytes (87). Subsequent to this intervention,

573 mosquito vectors infected with parasites prior to the intervention or from contact with subsets of the

574 population not covered by the initial round serve as a reservoir for infection. Thus 'cleared' hosts start to

575 become infected again from continued exposure. The longer the interval  $\Delta$ , the higher the prevalence of

576 malaria reached within the target population.

577 We initially make no assumptions about feedbacks associated with transmission, and additionally

578 disregard recovery without treatment, since time intervals to recovery are typically long. Supporting this,

published estimates of the distribution of duration of untreated *P. falciparum* infections (mean duration

approximately 180 days (41, 42)) indicate that the probability of recovery without treatment between our

581 longitudinal samples (mean sampling interval 57 days) and during a disruption interval (e.g., 2 months)

are very low.

## 583 6. Simulating additional control activities: Prophylaxis and vaccination

584 In addition to a primary intervention where a round of standard first line antimalarials (e.g., ACTs) is 585 applied to clear existing infections, various interventions that prolong the duration of protection may be

586 considered, from drug combinations with a longer prophylactic period to vaccination.

587 6.1 Mass drug administration with longer lasting chemoprevention

588 Including a longer-lived antimalarial (e.g., sulphadoxine-pyrimethamine, SP, or dihydroartemisinin-

589 piperaquine, DP) can prevent reinfection for the duration of effective prophylaxis. We define the mean

590 duration of prophylaxis as *D*. We first consider a mass drug administration (MDA) scenario where all

individuals, regardless of infection status, are given the ACT treatment paired with a prophylactic. When

- used to prevent reinfection for clinical cases this has been termed post-discharge malaria prophylaxis
- (PDMC). We also consider application in a mass test and treat (MTaT) activity where only individuals
   identified as positive for malaria infection receive the chemoprevention (see Table S1 for definitions).
- identified as positive for malaria infection receive the chemoprevention (see **Table S1** for definitions).
- 595 Because the drugs likely to be used in PDMC, MDA, and MTaT scenarios are the same as those for
- seasonal malaria chemoprevention (SMC) and intermittent preventive treatment (IPT), and thus have the
- 597 same duration of protection, the return time for all can be modeled as  $D + \Delta_c$ .

598

### 599 Table S1: World Health Organization assessed drug-based malaria interventions

Intervention	Definition
Mass Drug Administration (MDA)	Presumptive treatment of a large proportion of the population. In the simplest form, performed with a standard first-line anti-malarial (e.g., ACTs in Africa). <i>Aliases and derivatives</i> : Equivalent to MTaT when combined with diagnostic screening prior to treatment. Termed targeted drug administration (TDA) when applied to a selected subpopulation and reactive drug administration (RDA) when performed reactively for an observed infection cluster.
Post Discharge Malaria Chemoprevention (PDMC)	Addition of a longer lasting antimalarial (e.g., SP) for a prophylactic effect for treated individuals. <i>Aliases and derivatives</i> : If applied proactively for a season or year, equivalent to SMC/PMC/IPT
Mass Test and Treat (MTaT)	Testing, regardless of symptoms, a large proportion of the population and providing treatment for those testing positive. <i>Aliases and derivatives</i> : Sometimes termed Mass Screen and Treat (MSaT); targeted test and treat (TTaT) when applied to a selected subpopulation.
Intermittent Preventive Treatment (IPT)	The regular (e.g., monthly) administration of a curative antimalarial dose to curtail infections and prevent new infections. <i>Aliases and derivatives</i> : Often targeted to pregnant women (IPTp) and infants (IPTi). Equivalent to SMC/PMC.
Seasonal/Perennial Malaria Chemoprophylaxis (SMC/PMC)	Equivalent to IPT, the use of a full treatment course of antimalarials at regular intervals to reduce the risk of malaria infection. Recently recommended for scale up to more geographic areas and children over 5 <i>Aliases and derivatives</i> : SMC when targeted to the season with high transmission, PMC when year-round.

600

601

602 *6.2 Vaccination* 

Vaccination with the currently available antimalarial vaccines may provide a benefit in reducing clinical
cases when providing access to treatment or chemoprevention is unlikely. We use estimates of the
efficacy of antimalarial vaccines against clinical malaria reported from clinical trials for the RTS,S
(approx. 55%) (49) and R21 vaccines (approx. 75%) (54, 88).

607 In the simplest analysis, the expected number of clinical cases results from the rate of exposure,  $\lambda$ , giving 608 the probability of being infected over an interval, and the probability of infection being asymptomatic (*a*) 609 or symptomatic (s = 1 - a). Given no data on efficacy against infection ( $E_i$ ) for currently approved 610 vaccines, we conservatively assume  $E_i = 0$ . For a proportion, *v*, of children fully vaccinated at the 611 beginning of cyclone season, with a vaccine of efficacy of  $E_s$  (defined as reduction in probability of

612 symptomatic malaria), we estimate the probability of symptomatic infection among children over an

613 interval of length *t* following cessation of intervention due to a disruption:

614  $Pr(symptomatic infection) = v \times (1 - e^{-\lambda t}) \times (1 - E_i) \times s \times (1 - E_s) + (1 - v) \times (1 - e^{-\lambda t}) \times s$ 

615 See **Table S2** for parameter definitions and estimates.

## 616

	Parameter	Definition	Range	
	$1 - e^{-\lambda t}$	Proportion of uninfected individuals that test positive during interval <i>t</i>	0.01-1.0	
	v	Vaccination coverage	0-100%	
	S	Proportion of infected individuals reporting symptoms	0.1-1.0	
	$E_s$	Efficacy against symptomatic infection for vaccination	0-100%	
618 610				
620				
624				
621				
622				
623				
624				
625				
626				
020				
627				
628				
629				
630				
631				
602				
632				
633				
634				

### 617 Table S2. Parameter definitions used in vaccination modeling

# 635 Supporting Information

637

638

### 636 Figure S1. Sampling for the Mananjary malaria cohort study



639 1A: The proportion of enrolled individuals unsampled, negative, or positive by rapid diagnostic test (RDT) per time
640 point from baseline (T0) to final sample (T10) (all sites combined). 1B: Distribution of the number of observations
641 per individual (site code colors and order follow Figure 2C). 1C: Distribution of the interval in days between
642 samples.

## 643 Figure S2. Force of infection (FOI) by age



645 Observed variation in the force of infection by age for the 10 sample sites in Mananjary district, Madagascar (site646 code colors and order follow Figure 2C). Data shown for the month of January.

### 661 Figure S3. Accounting for imperfect RDT diagnostic accuracy



From 500 simulated trials, the force of infection (FOI) per day for a given sensitivity and specificity. Sites are ordered from lowest to highest observed rate of infection. Dashed vertical lines show the mean FOI from 500 simulations. For low infection sites (e.g., Sites MNJ.06 and MNJ.04, shown at top left), reduced sensitivity increases estimates of FOI (e.g., FOI increases from an initial estimate  $6.3 \times 10^{-4}$  to a mean estimate of  $2.7 \times 10^{-3}$  for sensitivity and specificity = 90%). This indicates for low infection rate sites, our estimates for the probability of infection over a time interval are conservative, with false negative rapid diagnostic tests contributing to a higher probability of infection. For high infection sites (e.g., Sites MNJ.01 and MNJ.10, shown at bottom right) estimates of FOI are relatively invariant across the range of sensitivity and specificity values explored. False negatives and false positives largely offset such that the initial FOI estimate  $7.19 \times 10^{-3}$  is similar to the mean estimate  $(7.16 \times 10^{-3})$  $^{3}$ ) from the 500 simulated trials with sensitivity and specificity at 90%. 

- ----





686 The percent of rapid diagnostic test (RDT) positive individuals reporting any fever within the last two weeks of

screening. Error bars show the 95% confidence intervals using the Clopper and Pearson (1934) method asimplemented in the R binom.test function.







The proportion of individuals reporting sleeping under a bednet in the last 24 hours and if reporting bednet was
damaged (due to holes, tears, or other damage). To the right, change in the proportion of individuals reporting not
using a bednet for sampling time points before and after two cyclones. Error bars show the 95% confidence intervals
using the Clopper and Pearson (1934) method as implemented in the R binom.test function.

- . \_ •

### 715 Figure S6. Simulating partial vaccination



716



718 Top: Probability tree of the outcomes of malaria infection under partial vaccination. From the probability tree in 719 Figure 4A, the vaccinated branch can be separated into partially and fully vaccinated sub-branches. Shown here 720 assuming protection against infection,  $E_i = 0$ , and protection against symptoms for fully vaccinated individuals  $E_s$  is 721 greater than the mean protection against symptoms for partially vaccinated individuals  $E_{partial}$ . Bottom: The percent 722 reduction in the number of expected symptomatic infections across a range of partial vaccination rates with partial 723 vaccine efficacy. Two example scenarios are shown where 50% of the targeted population is fully vaccinated and 0-724 50% of the population is partially vaccinated with protection varying from 0 to equaling the efficacy seen in fully 725 vaccinated individuals  $(E_s)$ . The shaded area shows the scenarios with sufficient efficacy and coverage to observe a 726 50% reduction in symptomatic infections.



### 728 Figure S7. Sensitivity analyses for vaccination parameters



For the targeted subpopulation (i.e., children), the number of symptomatic malaria infections averted by vaccination
with efficacy against symptoms *Es*. Rows show results for four levels of infection rates, expressed as the cumulative
proportion of the population expected to be infected over the time interval considered. Columns show results for
three values for the probability with which infections become symptomatic.

### Data S1 756

Tropical cyclones and related humanitarian disasters in Madagascar since 1980 (xlsx) 757

### Data S2 758

- 759 Locality information for study sites in Mananjary district, Madagascar including site codes,
- administrative division names, and coordinates of midpoints (xslx) 760

### Data S3 761

762 Line list data of individual rapid diagnostic test (RDT) results and sample dates (csv)

### **Data S4** 763

- 764 Tropical cyclone tracks data from IBTrACS (csv)
- 765 Accessed from: https://www.ncei.noaa.gov/data/international-best-track-archive-for-climate-stewardship-
- 766 ibtracs/v04r00/access/csv/

#### Data S5 767

Global estimates of average annual tropical cyclone exposure from Jing et al 2023 (39) (csv) 768

### Data S6 769

- 770 Spatial estimates of *Plasmodium falciparum* incidence rate for 2020 from the Malaria Atlas Project (tif)
- 771
- 772 Accessed from: https://data.malariaatlas.org/

### Data S7 773

774 National level estimated incidence of malaria from the World Health Organization (xlsx)

### Data S8 775

776 Bednet usage questionnaire response data for the Mananjary cohort study (csv)

#### Data S9 777

778 Symptoms questionnaire response data for the Mananjary cohort study (csv)

- 780
- 781
- 782
- 783

## 784 **References and Notes:**

- "World Malaria Report 2023" (Global Malaria Programme, World Health Organization, 2023); https://www.who.int/publications/i/item/9789240086173.
- J. R. Poespoprodjo, N. M. Douglas, D. Ansong, S. Kho, N. M. Anstey, Malaria. *Lancet* **402**, 2328–2345 (2023).
- E. A. Mordecai, J. M. Caldwell, M. K. Grossman, C. A. Lippi, L. R. Johnson, M. Neira, J. R.
   Rohr, S. J. Ryan, V. Savage, M. S. Shocket, R. Sippy, A. M. Stewart Ibarra, M. B. Thomas,
   O. Villena, Thermal biology of mosquito-borne disease. *Ecol. Lett.* 22, 1690–1708 (2019).
- 4. O. C. Villena, S. J. Ryan, C. C. Murdock, L. R. Johnson, Temperature impacts the
  environmental suitability for malaria transmission by Anopheles gambiae and Anopheles
  stephensi. *Ecology* **103**, e3685 (2022).
- 5. W. M. de Souza, S. C. Weaver, Effects of climate change and human activities on vectorborne diseases. *Nat. Rev. Microbiol.*, doi: 10.1038/s41579-024-01026-0 (2024).
- 6. E. A. Mordecai, K. P. Paaijmans, L. R. Johnson, C. Balzer, T. Ben-Horin, E. de Moor, A.
  McNally, S. Pawar, S. J. Ryan, T. C. Smith, K. D. Lafferty, Optimal temperature for malaria
  transmission is dramatically lower than previously predicted. *Ecol. Lett.* 16, 22–30 (2013).
- K. P. Paaijmans, A. F. Read, M. B. Thomas, Understanding the link between malaria risk
  and climate. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 13844–13849 (2009).
- 802 8. S. J. Ryan, C. A. Lippi, F. Zermoglio, Shifting transmission risk for malaria in Africa with 803 climate change: a framework for planning and intervention. *Malar. J.* **19**, 170 (2020).
- 804 9. A. S. Siraj, M. Santos-Vega, M. J. Bouma, D. Yadeta, D. Ruiz Carrascal, M. Pascual,
  805 Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. *Science*806 343, 1154–1158 (2014).
- 807 10. C. Caminade, S. Kovats, J. Rocklov, A. M. Tompkins, A. P. Morse, F. J. Colón-González,
  808 H. Stenlund, P. Martens, S. J. Lloyd, Impact of climate change on global malaria
  809 distribution. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 3286–3291 (2014).
- K. T. Bhatia, G. A. Vecchi, T. R. Knutson, H. Murakami, J. Kossin, K. W. Dixon, C. E.
  Whitlock, Recent increases in tropical cyclone intensification rates. *Nat. Commun.* **10**, 635 (2019).
- J. B. Elsner, J. P. Kossin, T. H. Jagger, The increasing intensity of the strongest tropical
   cyclones. *Nature* 455, 92–95 (2008).
- 815 13. L. Li, P. Chakraborty, Slower decay of landfalling hurricanes in a warming world. *Nature*816 587, 230–234 (2020).
- 817 14. S. Wang, R. Toumi, Recent migration of tropical cyclones toward coasts. *Science* 371, 514–517 (2021).
- A. M. D. Ortiz, P. L. C. Chua, D. Salvador Jr, C. Dyngeland, J. D. G. Albao Jr, R. A.
   Abesamis, Impacts of tropical cyclones on food security, health and biodiversity. *Bull. World*

- 821 *Health Organ.* **101**, 152–154 (2023).
- 16. J. M. Shultz, J. Russell, Z. Espinel, Epidemiology of tropical cyclones: the dynamics of disaster, disease, and development. *Epidemiol. Rev.* **27**, 21–35 (2005).
- R. M. Parks, G. B. Anderson, R. C. Nethery, A. Navas-Acien, F. Dominici, M.-A.
  Kioumourtzoglou, Tropical cyclone exposure is associated with increased hospitalization rates in older adults. *Nat. Commun.* **12**, 1545 (2021).
- 18. T. Alcayna, I. Fletcher, R. Gibb, L. Tremblay, S. Funk, B. Rao, R. Lowe, Climate-sensitive
  disease outbreaks in the aftermath of extreme climatic events: A scoping review. *One Earth*5, 336–350 (2022).
- K. L. Ebi, J. Vanos, J. W. Baldwin, J. E. Bell, D. M. Hondula, N. A. Errett, K. Hayes, C. E.
  Reid, S. Saha, J. Spector, P. Berry, Extreme Weather and Climate Change: Population
  Health and Health System Implications. *Annu. Rev. Public Health* 42, 293–315 (2021).
- 833 20. H. Nissan, I. Ukawuba, M. Thomson, Climate-proofing a malaria eradication strategy.
   834 *Malar. J.* 20, 190 (2021).
- 835 21. K. M. Searle, D. E. Earland, A. Francisco Bibe, A. Novela, V. Muhiro, J. L. Ferrão, Long836 lasting household damage from Cyclone Idai increases malaria risk in rural western
  837 Mozambique. *Sci. Rep.* 13, 21590 (2023).
- 838 22. S. Devi, Cyclone Idai: 1 month later, devastation persists. *Lancet* **393**, 1585 (2019).
- A. Pozniak, A. Atzori, C. Marotta, F. Di Gennaro, G. Putoto, HIV continuity of care after
  Cyclone Idai in Mozambique. *Lancet HIV* 7, e159–e160 (2020).
- Q. Fernandes, O. Augusto, S. Chicumbe, L. Anselmi, B. H. Wagenaar, R. Marlene, S.
  Agostinho, S. Gimbel, J. Pfeiffer, C. Inguane, D. M. Uetela, J. Crocker, I. Ramiro, B.
  Matsinhe, S. Tembe, N. Carimo, S. Gloyd, I. Manhiça, E. Tavede, P. Felimone, K. Sherr,
  Maternal and Child Health Care Service Disruptions and Recovery in Mozambique After
  Cyclone Idai: An Uncontrolled Interrupted Time Series Analysis. *Glob Health Sci Pract* 10
  (2022).
- St. J. E. Coalson, E. J. Anderson, E. M. Santos, V. Madera Garcia, J. K. Romine, B.
  Dominguez, D. M. Richard, A. C. Little, M. H. Hayden, K. C. Ernst, The Complex
  Epidemiological Relationship between Flooding Events and Human Outbreaks of MosquitoBorne Diseases: A Scoping Review. *Environ. Health Perspect.* **129**, 96002 (2021).
- 26. J. T. Watson, M. Gayer, M. A. Connolly, Epidemics after natural disasters. *Emerg. Infect. Dis.* 13, 1–5 (2007).
- 853 27. IPCC, Climate Change 2021: The Physical Science Basis. Contribution of Working Group I
  854 to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change
  855 (Cambridge University Press, Cambridge, United Kingdom and New York, NY, USA, 2021).
- 28. J. P. Kossin, K. R. Knapp, T. L. Olander, C. S. Velden, Global increase in major tropical
  cyclone exceedance probability over the past four decades. *Proc. Natl. Acad. Sci. U. S. A.*117, 11975–11980 (2020).
- 29. "Cyclone Freddy deepens health risks in worst-hit countries" (World Health Organization

- (WHO) African Region, 2023); https://www.afro.who.int/news/cyclone-freddy-deepens health-risks-worst-hit-countries.
- 30. "Mobilizing health assistance after deadly cyclones devastate Madagascar" (World Health
   Organization (WHO) African Region, 2022); https://www.afro.who.int/photo-story/mobilizing health-assistance-after-deadly-cyclones-devastate-madagascar.
- 865 31. "In Madagascar, mobile clinics bolster health surveillance during cyclones" (World Health
  866 Organization (WHO) Regional Office for Africa, 2023);
  867 https://www.afro.who.int/countries/madagascar/news/madagascar-mobile-clinics-bolster868 health-surveillance-during-cyclones.
- 869 32. "Outbreaks and emergencies bulletin, week 12: 13 19 march 2023: Cyclone Freddy in the
  870 WHO African Region" (12, World Health Organization (WHO) African Region, 2023);
  871 https://www.afro.who.int/countries/togo/publication/outbreaks-and-emergencies-bulletin872 week-12-13-19-march-2023.
- 873 33. D. Delforge, V. Wathelet, R. Below, C. L. Sofia, M. Tonnelier, J. van Loenhout, N.
  874 Speybroeck, EM-DAT: The Emergency Events Database, *Research Square* (2023).
  875 https://doi.org/10.21203/rs.3.rs-3807553/v1.
- 876 34. FEL Otto, M Zachariah, P Wolski, I Pinto, R Barimalala, B Nhamtumbo, R Bonnet, R 877 Vautard, S Philip, S Kew, LN Luu, D Heinrich, M Vahlberg, R Singh, J Arrighi, L 878 Thalheimer, Mv Aalst, S Li, J Sun, G Vecchi, LJ Harrington, "Climate change increased 879 rainfall associated with tropical cyclones hitting highly vulnerable communities in 880 Madagascar, Mozambigue & Malawi" (World Weather Attribution (WWA) Initiative, 2022); 881 https://www.worldweatherattribution.org/climate-change-increased-rainfall-associated-with-882 tropical-cyclones-hitting-highly-vulnerable-communities-in-madagascar-mozambigue-883 malawi/.
- 884 35. K. R. Knapp, M. C. Kruk, D. H. Levinson, H. J. Diamond, C. J. Neumann, The International
  885 Best Track Archive for Climate Stewardship (IBTrACS): Unifying Tropical Cyclone Data.
  886 *Bull. Am. Meteorol. Soc.* 91, 363–376 (2010).
- 887 36. K. R. Knapp, H. J. Diamond, J. P. Kossin, M. C. Kruk, C. J. Schreck, International best track archive for climate stewardship (IBTrACS) project, version 4, NOAA National Centers for Environmental Information (2018); https://doi.org/10.25921/82TY-9E16.
- 37. D. A. Pfeffer, T. C. D. Lucas, D. May, J. Harris, J. Rozier, K. A. Twohig, U. Dalrymple, C. A.
  Guerra, C. L. Moyes, M. Thorn, M. Nguyen, S. Bhatt, E. Cameron, D. J. Weiss, R. E.
  Howes, K. E. Battle, H. S. Gibson, P. W. Gething, malariaAtlas: an R interface to global
  malariometric data hosted by the Malaria Atlas Project. *Malar. J.* **17**, 352 (2018).
- 894 38. C. P. T. G. Zehr, *Biscale: Tools and Palettes for Bivariate Thematic Mapping R Package* 895 (2022; https://chris-prener.github.io/biscale/authors.html).
- 896 39. R. Jing, S. Heft-Neal, D. R. Chavas, M. Griswold, Z. Wang, A. Clark-Ginsberg, D. Guha897 Sapir, E. Bendavid, Z. Wagner, Global population profile of tropical cyclone exposure from
  898 2002 to 2019. *Nature* 626, 549–554 (2024).
- 40. The Global Health Observatory, World Health Organization, Malaria incidence per 1 000 population at risk per year (estimated) By country, World Health Organization (2023);

- 901 https://apps.who.int/gho/data/node.main.MALARIAESTINCIDENCE?lang=en.
- 902 41. H. C. Slater, A. Ross, I. Felger, N. E. Hofmann, L. Robinson, J. Cook, B. P. Gonçalves, A. 903 Björkman, A. L. Ouedraogo, U. Morris, M. Msellem, C. Koepfli, I. Mueller, F. Tadesse, E. 904 Gadisa, S. Das, G. Domingo, M. Kapulu, J. Midega, S. Owusu-Agvei, C. Nabet, R. 905 Piarroux, O. Doumbo, S. N. Doumbo, K. Koram, N. Lucchi, V. Udhayakumar, J. Mosha, A. Tiono, D. Chandramohan, R. Gosling, F. Mwingira, R. Sauerwein, R. Paul, E. M. Riley, N. 906 907 J. White, F. Nosten, M. Imwong, T. Bousema, C. Drakeley, L. C. Okell, The temporal 908 dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to 909 parasite density. Nat. Commun. 10, 1433 (2019).
- 42. E. A. Ashley, N. J. White, The duration of Plasmodium falciparum infections. *Malar. J.* 13, 500 (2014).
- 43. European Space Agency, Sinergise, OpenTopography Copernicus global digital elevation
   models, (2021); https://doi.org/10.5069/G9028PQB.
- 914 44. B. L. Rice, C. D. Golden, H. J. Randriamady, A. A. N. A. Rakotomalala, M. A. Vonona, E. J.
  915 G. Anjaranirina, J. Hazen, M. C. Castro, C. J. E. Metcalf, D. L. Hartl, Fine-scale variation in
  916 malaria prevalence across ecological regions in Madagascar: a cross-sectional study. *BMC*917 *Public Health* **21**, 1018 (2021).
- 918 45. "U.S. President's Malaria Initiative Madagascar Malaria Operational Plan FY 2023"
  919 (President's Malaria Initiative, 2023); https://www.pmi.gov/resources/malaria-operational-920 plans-mops/.
- 46. M. T. Bretscher, P. Dahal, J. Griffin, K. Stepniewska, Q. Bassat, E. Baudin, U.
  D'Alessandro, A. A. Djimde, G. Dorsey, E. Espié, B. Fofana, R. González, E. Juma, C.
  Karema, E. Lasry, B. Lell, N. Lima, C. Menéndez, G. Mombo-Ngoma, C. Moreira, F.
  Nikiema, J. B. Ouédraogo, S. G. Staedke, H. Tinto, I. Valea, A. Yeka, A. C. Ghani, P. J.
  Guerin, L. C. Okell, The duration of chemoprophylaxis against malaria after treatment with
  artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and
  pfcrt 76T: a meta-analysis of individual patient data. *BMC Med.* 18, 47 (2020).
- 47. M. Cairns, I. Carneiro, P. Milligan, S. Owusu-Agyei, T. Awine, R. Gosling, B. Greenwood,
  D. Chandramohan, Duration of protection against malaria and anaemia provided by
  intermittent preventive treatment in infants in Navrongo, Ghana. *PLoS One* 3, e2227
  (2008).
- 48. M. Cairns, A. Barry, I. Zongo, I. Sagara, S. R. Yerbanga, M. Diarra, C. Zoungrana, D.
  Issiaka, A. A. Sienou, A. Tapily, K. Sanogo, M. Kaya, S. Traore, K. Diarra, H. Yalcouye, Y.
  Sidibe, A. Haro, I. Thera, P. Snell, J. Grant, H. Tinto, P. Milligan, D. Chandramohan, B.
  Greenwood, A. Dicko, J. B. Ouedraogo, The duration of protection against clinical malaria
  provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria
  chemoprevention versus either intervention given alone. *BMC Med.* 20, 352 (2022).
- RTS,S Clinical Trials Partnership, S. T. Agnandji, B. Lell, S. S. Soulanoudjingar, J. F.
   Fernandes, B. P. Abossolo, C. Conzelmann, B. G. N. O. Methogo, Y. Doucka, A. Flamen,
   B. Mordmüller, S. Issifou, P. G. Kremsner, J. Sacarlal, P. Aide, M. Lanaspa, J. J. Aponte, A.
   Nhamuave, D. Quelhas, Q. Bassat, S. Mandjate, E. Macete, P. Alonso, S. Abdulla, N.
   Salim, O. Juma, M. Shomari, K. Shubis, F. Machera, A. S. Hamad, R. Minja, A. Mtoro, A.
   Sykes, S. Ahmed, A. M. Urassa, A. M. Ali, G. Mwangoka, M. Tanner, H. Tinto, U.

944 D'Alessandro, H. Sorgho, I. Valea, M. C. Tahita, W. Kaboré, S. Ouédraogo, Y. Sandrine, R. 945 T. Guiguemdé, J. B. Ouédraogo, M. J. Hamel, S. Kariuki, C. Odero, M. Oneko, K. Otieno, N. Awino, J. Omoto, J. Williamson, V. Muturi-Kioi, K. F. Laserson, L. Slutsker, W. Otieno, L. 946 947 Otieno, O. Nekove, S. Gondi, A. Otieno, B. Ogutu, R. Wasuna, V. Owira, D. Jones, A. A. Onyango, P. Njuguna, R. Chilengi, P. Akoo, C. Kerubo, J. Gitaka, C. Maingi, T. Lang, A. 948 949 Olotu, B. Tsofa, P. Bejon, N. Peshu, K. Marsh, S. Owusu-Agyei, K. P. Asante, K. Osei-950 Kwakye, O. Boahen, S. Ayamba, K. Kayan, R. Owusu-Ofori, D. Dosoo, I. Asante, G. Adjei, 951 G. Adjei, D. Chandramohan, B. Greenwood, J. Lusingu, S. Gesase, A. Malabeja, O. Abdul, 952 H. Kilavo, C. Mahende, E. Liheluka, M. Lemnge, T. Theander, C. Drakeley, D. Ansong, T. 953 Agbenyega, S. Adjei, H. O. Boateng, T. Rettig, J. Bawa, J. Sylverken, D. Sambian, A. 954 Aqvekum, L. Owusu, F. Martinson, I. Hoffman, T. Mvalo, P. Kamthunzi, R. Nkomo, A. 955 Msika, A. Jumbe, N. Chome, D. Nyakuipa, J. Chintedza, W. R. Ballou, M. Bruls, J. Cohen, 956 Y. Guerra, E. Jongert, D. Lapierre, A. Leach, M. Lievens, O. Ofori-Anyinam, J. Vekemans, 957 T. Carter, D. Leboulleux, C. Louca, A. Radford, B. Savarese, D. Schellenberg, M. Sillman, 958 P. Vansadia, First results of phase 3 trial of RTS.S/AS01 malaria vaccine in African 959 children. N. Engl. J. Med. 365, 1863-1875 (2011).

- 50. M. S. Datoo, A. Dicko, H. Tinto, J.-B. Ouédraogo, M. Hamaluba, A. Olotu, E. Beaumont, F. Ramos Lopez, H. M. Natama, S. Weston, M. Chemba, Y. D. Compaore, D. Issiaka, D. Salou, A. M. Some, S. Omenda, A. Lawrie, P. Bejon, H. Rao, D. Chandramohan, R. Roberts, S. Bharati, L. Stockdale, S. Gairola, B. M. Greenwood, K. J. Ewer, J. Bradley, P. S. Kulkarni, U. Shaligram, A. V. S. Hill, R21/Matrix-M Phase 3 Trial Group, Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. *Lancet* 403, 533–544 (2024).
- 51. T. Bousema, L. Okell, I. Felger, C. Drakeley, Asymptomatic malaria infections: detectability,
   transmissibility and public health relevance. *Nat. Rev. Microbiol.* **12**, 833–840 (2014).
- 52. E. Rajaonarifara, M. H. Bonds, A. C. Miller, F. A. Ihantamalala, L. Cordier, B. Razafinjato,
  F. H. Rafenoarimalala, K. E. Finnegan, R. J. L. Rakotonanahary, G. Cowley, B.
  Ratsimbazafy, F. Razafimamonjy, M. Randriamanambintsoa, E. M. RazaFanomezanjanahary, A. Randrianambinina, C. J. Metcalf, B. Roche, A. Garchitorena,
  Impact of health system strengthening on delivery strategies to improve child immunisation
  coverage and inequalities in rural Madagascar. *BMJ Glob Health* 7 (2022).
- 53. F. K. Jones, K. Mensah, J.-M. Heraud, F. M. Randriatsarafara, C. J. E. Metcalf, A.
  Wesolowski, The Challenge of Achieving Immunity Through Multiple-Dose Vaccines in Madagascar. *Am. J. Epidemiol.* **190**, 2085–2093 (2021).
- 54. M. S. Datoo, H. M. Natama, A. Somé, D. Bellamy, O. Traoré, T. Rouamba, M. C. Tahita, N.
  F. A. Ido, P. Yameogo, D. Valia, A. Millogo, F. Ouedraogo, R. Soma, S. Sawadogo, F.
  Sorgho, K. Derra, E. Rouamba, F. Ramos-Lopez, M. Cairns, S. Provstgaard-Morys, J.
  Aboagye, A. Lawrie, R. Roberts, I. Valéa, H. Sorgho, N. Williams, G. Glenn, L. Fries, J.
  Reimer, K. J. Ewer, U. Shaligram, A. V. S. Hill, H. Tinto, Efficacy and immunogenicity of
  R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina
  Faso: a phase 1/2b randomised controlled trial. *Lancet Infect. Dis.* 22, 1728–1736 (2022).
- 985 55. Institut National de la Statistique (INSTAT) et ICF, Enquête Démographique et de Santé à
   986 Madagascar (EDSMD-V) 2021 (2022).
- 987 56. Intergovernmental Panel on Climate Change (IPCC), "Weather and Climate Extreme
   988 Events in a Changing Climate" in *Climate Change 2021 The Physical Science Basis:*

989 Working Group I Contribution to the Sixth Assessment Report of the Intergovernmental 990 Panel on Climate Change (Cambridge University Press, 2023), pp. 1513–1766.

- 57. H. C. Slater, A. Ross, A. L. Ouédraogo, L. J. White, C. Nguon, P. G. T. Walker, P. Ngor, R.
  Aguas, S. P. Silal, A. M. Dondorp, P. La Barre, R. Burton, R. W. Sauerwein, C. Drakeley, T.
  A. Smith, T. Bousema, A. C. Ghani, Assessing the impact of next-generation rapid
  diagnostic tests on Plasmodium falciparum malaria elimination strategies. *Nature* 528,
  S94–101 (2015).
- 58. L. Wu, L. L. van den Hoogen, H. Slater, P. G. T. Walker, A. C. Ghani, C. J. Drakeley, L. C.
  Okell, Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies. *Nature* 528, S86–93 (2015).
- 59. J. T. Lin, D. L. Saunders, S. R. Meshnick, The role of submicroscopic parasitemia in malaria transmission: what is the evidence? *Trends Parasitol.* **30**, 183–190 (2014).
- 1001 60. "WHO guidelines for malaria" (World Health Organization, Geneva, 2023);
   1002 https://www.ncbi.nlm.nih.gov/pubmed/36580567.
- 1003 61. N. Schmit, H. M. Topazian, H. M. Natama, D. Bellamy, O. Traoré, M. A. Somé, T.
  1004 Rouamba, M. C. Tahita, M. D. A. Bonko, A. Sourabié, H. Sorgho, L. Stockdale, S.
  1005 Provstgaard-Morys, J. Aboagye, D. Woods, K. Rapi, M. S. Datoo, F. R. Lopez, G. D.
  1006 Charles, K. McCain, J.-B. Ouedraogo, M. Hamaluba, A. Olotu, A. Dicko, H. Tinto, A. V. S.
  1007 Hill, K. J. Ewer, A. C. Ghani, P. Winskill, The public health impact and cost-effectiveness of
  1008 the R21/Matrix-M malaria vaccine: a mathematical modelling study. *Lancet Infect. Dis.*, doi:
  10.1016/S1473-3099(23)00816-2 (2024).
- 1010
  62. H. M. Topazian, N. Schmit, I. Gerard-Ursin, G. D. Charles, H. Thompson, A. C. Ghani, P.
  1011
  Winskill, Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine
  1012
  compared to investment in vector control or chemoprophylaxis. *Vaccine* 41, 3215–3223
  1013
  (2023).
- 1014
  63. O. O. Adeshina, S. Nyame, J. Milner, A. Milojevic, K. P. Asante, Barriers and facilitators to 1015 nationwide implementation of the malaria vaccine in Ghana. *Health Policy Plan.* 38, 28–37 1016 (2023).
- 1017 64. World Health Organization, *Malaria Control in Humanitarian Emergencies: An Inter-Agency* 1018 *Field Handbook* (World Health Organization, 2013).
- M. Burns, M. Rowland, R. N'Guessan, I. Carneiro, A. Beeche, S. S. Ruiz, S. Kamara, W.
  Takken, P. Carnevale, R. Allan, Insecticide-treated plastic sheeting for emergency malaria
  prevention and shelter among displaced populations: an observational cohort study in a
  refugee setting in Sierra Leone. *Am. J. Trop. Med. Hyg.* 87, 242–250 (2012).
- 1023
   1024
   1024
   1024
   1025
   1025
   1026
   1027
   1028
   1029
   1029
   1029
   1020
   1020
   1021
   1021
   1021
   1022
   1022
   1023
   1024
   1025
   1025
   1025
   1026
   1027
   1027
   1028
   1029
   1029
   1020
   1020
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   1021
   <li
- 1026 67. World Health Organization, *Operational Framework for Building Climate Resilient Health* 1027 *Systems* (World Health Organization, Genève, Switzerland, 2015).
- 1028 68. M. Romanello, A. McGushin, C. Di Napoli, P. Drummond, N. Hughes, L. Jamart, H.

1029 Kennard, P. Lampard, B. Solano Rodriguez, N. Arnell, S. Aveb-Karlsson, K. Belesova, W. 1030 Cai, D. Campbell-Lendrum, S. Capstick, J. Chambers, L. Chu, L. Ciampi, C. Dalin, N. 1031 Dasandi, S. Dasgupta, M. Davies, P. Dominguez-Salas, R. Dubrow, K. L. Ebi, M. 1032 Eckelman, P. Ekins, L. E. Escobar, L. Georgeson, D. Grace, H. Graham, S. H. Gunther, S. 1033 Hartinger, K. He, C. Heaviside, J. Hess, S.-C. Hsu, S. Jankin, M. P. Jimenez, I. Kelman, G. 1034 Kiesewetter, P. L. Kinney, T. Kjellstrom, D. Kniveton, J. K. W. Lee, B. Lemke, Y. Liu, Z. Liu, 1035 M. Lott, R. Lowe, J. Martinez-Urtaza, M. Maslin, L. McAllister, C. McMichael, Z. Mi, J. 1036 Milner, K. Minor, N. Mohajeri, M. Moradi-Lakeh, K. Morrissey, S. Munzert, K. A. Murray, T. 1037 Neville, M. Nilsson, N. Obradovich, M. O. Sewe, T. Oreszczyn, M. Otto, F. Owfi, O. Pearman, D. Pencheon, M. Rabbaniha, E. Robinson, J. Rocklöv, R. N. Salas, J. C. 1038 1039 Semenza, J. Sherman, L. Shi, M. Springmann, M. Tabatabaei, J. Taylor, J. Trinanes, J. 1040 Shumake-Guillemot, B. Vu, F. Wagner, P. Wilkinson, M. Winning, M. Yglesias, S. Zhang, P. 1041 Gong, H. Montgomery, A. Costello, I. Hamilton, The 2021 report of the Lancet Countdown 1042 on health and climate change: code red for a healthy future. Lancet 398, 1619-1662 1043 (2021).

- M. E. Beatty, E. Hunsperger, E. Long, J. Schürch, S. Jain, R. Colindres, G. Lerebours, Y.M. Bernard, J. G. Dobbins, M. Brown, G. G. Clark, Mosquitoborne infections after Hurricane
  Jeanne, Haiti, 2004. *Emerg. Infect. Dis.* **13**, 308–310 (2007).
- T. Fürst, G. Raso, C. A. Acka, A. B. Tschannen, E. K. N'Goran, J. Utzinger, Dynamics of
   socioeconomic risk factors for neglected tropical diseases and malaria in an armed conflict.
   *PLoS Negl. Trop. Dis.* 3, e513 (2009).
- 1050 71. L. Sedda, Q. Qi, A. J. Tatem, A geostatistical analysis of the association between armed
   1051 conflicts and Plasmodium falciparum malaria in Africa, 1997-2010. *Malar. J.* 14, 500 (2015).
- 1052 72. M. A. Connolly, M. Gayer, M. J. Ryan, P. Salama, P. Spiegel, D. L. Heymann,
  1053 Communicable diseases in complex emergencies: impact and challenges. *Lancet* 364,
  1054 1974–1983 (2004).
- 1055 73. {Institut National de la Statistique-INSTAT/Madagascar, Programme National de lutte
  1056 contre le Paludisme-PNLP/Madagascar, Institut Pasteur de Madagascar 1057 IPM/Madagascar, and ICF International, *Enquête Sur Les Indicateurs Du Paludisme 2016*1058 *Madagascar* (Calverton, MD, USA : INSTAT, PNLP, IPM and ICF International., 2017).
- 1059 74. Institut National de la Statistique-INSTAT/Madagascar, Programme National de lutte contre
  1060 le Paludisme-PNLP/Madagascar, Institut Pasteur de Madagascar-IPM/Madagascar, ICF
  1061 International, *Madagascar Enquête Sur Les Indicateurs Du Paludisme (EIPM) 2013* (2013).
- 1062 75. Institut National de la Statistique/Madagascar, Programme National de Lutte contre le
   1063 Paludisme/Madagascar, ICF International, Madagascar Enquête sur les Indicateurs du
   1064 Paludisme à Madagascar (EIPMD) 2011. (2012).
- 76. R. Arambepola, S. H. Keddie, E. L. Collins, K. A. Twohig, P. Amratia, A. Bertozzi-Villa, E.
  G. Chestnutt, J. Harris, J. Millar, J. Rozier, S. F. Rumisha, T. L. Symons, C. Vargas-Ruiz,
  M. Andriamananjara, S. Rabeherisoa, A. C. Ratsimbasoa, R. E. Howes, D. J. Weiss, P. W.
  Gething, E. Cameron, Spatiotemporal mapping of malaria prevalence in Madagascar using
  routine surveillance and health survey data. *Sci. Rep.* 10, 18129 (2020).
- 1070 77. R. E. Howes, S. A. Mioramalala, B. Ramiranirina, T. Franchard, A. J. Rakotorahalahy, D.
   1071 Bisanzio, P. W. Gething, P. A. Zimmerman, A. Ratsimbasoa, Contemporary

- 1072 epidemiological overview of malaria in Madagascar: operational utility of reported routine 1073 case data for malaria control planning. *Malar. J.* **15**, 502 (2016).
- 1074
  78. M. Nguyen, R. E. Howes, T. C. D. Lucas, K. E. Battle, E. Cameron, H. S. Gibson, J. Rozier,
  1075
  S. Keddie, E. Collins, R. Arambepola, S. Y. Kang, C. Hendriks, A. Nandi, S. F. Rumisha, S.
  1076
  Bhatt, S. A. Mioramalala, M. A. Nambinisoa, F. Rakotomanana, P. W. Gething, D. J. Weiss,
  1077
  Mapping malaria seasonality in Madagascar using health facility data. *BMC Med.* 18, 26
  1078
  (2020).
- R. Ratovoson, A. Garchitorena, D. Kassie, J. A. Ravelonarivo, V. Andrianaranjaka, S.
   Razanatsiorimalala, A. Razafimandimby, F. Rakotomanana, L. Ohlstein, R.
   Mangahasimbola, S. A. N. Randrianirisoa, J. Razafindrakoto, C. M. Dentinger, J.
   Williamson, L. Kapesa, P. Piola, M. Randrianarivelojosia, J. Thwing, L. C. Steinhardt, L.
   Baril, Proactive community case management decreased malaria prevalence in rural
   Madagascar: results from a cluster randomized trial. *BMC Med.* 20, 322 (2022).
- 80. C. D. Golden, E. J. G. Anjaranirina, L. C. H. Fernald, D. L. Hartl, C. Kremen, D. A. Milner Jr,
  D. H. Ralalason, H. Ramihantaniarivo, H. Randriamady, B. L. Rice, B. Vaitla, S. K.
  Volkman, M. A. Vonona, S. S. Myers, Cohort Profile: The Madagascar Health and
  Environmental Research (MAHERY) study in north-eastern Madagascar. *Int. J. Epidemiol.*46, 1747–1748d (2017).
- 81. C. D. Golden, B. L. Rice, H. J. Randriamady, A. M. Vonona, J. F. Randrianasolo, A. N.
  Tafangy, M. Y. Andrianantenaina, N. J. Arisco, G. N. Emile, F. Lainandrasana, R. F. F.
  Mahonjolaza, H. P. Raelson, V. R. Rakotoarilalao, A. A. N. A. Rakotomalala, A. D.
  Rasamison, R. Mahery, M. L. Tantely, R. Girod, A. Annapragada, A. Wesolowski, A.
  Winter, D. L. Hartl, J. Hazen, C. J. E. Metcalf, Study Protocol: A Cross-Sectional
  Examination of Socio-Demographic and Ecological Determinants of Nutrition and Disease
  Across Madagascar. *Front Public Health* 8, 500 (2020).
- 82. B. L. Rice, C. D. Golden, E. J. G. Anjaranirina, C. M. Botelho, S. K. Volkman, D. L. Hartl,
  Genetic evidence that the Makira region in northeastern Madagascar is a hotspot of malaria
  transmission. *Malar. J.* **15**, 596 (2016).
- 83. S. Xiaodong, E. Tambo, W. Chun, C. Zhibin, D. Yan, W. Jian, W. Jiazhi, Z. Xiaonong,
  Diagnostic performance of CareStart<sup>™</sup> malaria HRP2/pLDH (Pf/pan) combo test versus
  standard microscopy on falciparum and vivax malaria between China-Myanmar endemic
  borders. *Malar. J.* **12**, 6 (2013).
- 84. G. M. Bwire, B. Ngasala, M. Kilonzi, W. P. Mikomangwa, F. F. Felician, A. A. R.
  Kamuhabwa, Diagnostic performance of CareStart<sup>™</sup> malaria HRP2/pLDH test in comparison with standard microscopy for detection of uncomplicated malaria infection among symptomatic patients, Eastern Coast of Tanzania. *Malar. J.* **18**, 354 (2019).
- 1108 85. D. A. Griffiths, A Catalytic Model of Infection for Measles. J. R. Stat. Soc. Ser. C Appl. Stat.
  1109 23, 330–339 (1974).
- 86. N. Hens, Z. Shkedy, M. Aerts, C. Faes, P. Van Damme, P. Beutels, *Modeling Infectious*Disease Parameters Based on Serological and Social Contact Data (Springer New York).
- 87. L. C. Okell, C. J. Drakeley, A. C. Ghani, T. Bousema, C. J. Sutherland, Reduction of
   transmission from malaria patients by artemisinin combination therapies: a pooled analysis

- 1114 of six randomized trials. *Malar. J.* **7**, 125 (2008).
- 88. M. S. Datoo, A. Dicko, H. Tinto, J.-B. Ouédraogo, M. Hamaluba, A. Olotu, E. Beaumont, F.
  Ramos-Lopez, H. Magloire Natama, S. Weston, M. Chemba, Y. D. Compaore, D. Issiaka,
- 1117 D. Salou, S. Omenda, A. Lawrie, P. Bejon, D. Chandramohan, R. Roberts, S. Bharati, L.
- 1118 Stockdale, B. Greenwood, K. Ewer, J. Bradley, C. S. Poonawalla, P. S. Kulkarni, U.
- 1119 Shaligram, A. V. S. Hill, A Phase III Randomised Controlled Trial Evaluating the Malaria
- 1120 Vaccine Candidate R21/Matrix-M<sup>™</sup> in African Children (2023).
- 1121 https://doi.org/10.2139/ssrn.4584076.